loading page

Novel use of imatinib to treat mandibular fibrous dysplasia in Noonan's syndrome
  • +1
  • Joshua W. Goldman,
  • Sean Edwards,
  • Rajen Mody,
  • Rama Jasty
Joshua W. Goldman
University of Michigan Department of Pediatrics

Corresponding Author:[email protected]

Author Profile
Sean Edwards
University of Michigan Department of Surgery
Author Profile
Rajen Mody
University of Michigan Department of Pediatrics
Author Profile
Rama Jasty
University of Michigan Department of Pediatrics
Author Profile

Abstract

Fibrous dysplasia of the mandible typically begins during toddler years and culminates during puberty. These lesions may cause jaw disfigurement and may not be amendable to surgery. Imatinib successfully has treated cherubism associated with SH3BP2 mutations, but similar lesions can present in other conditions such as Noonan syndrome. We report diagnosis of Noonan syndrome caused by a PTPN11 activating mutation and successful treatment of the fibrous dysplasia of the mandible with imatinib.